JALSG AML/MDS/CMML Clinical Observational Study (JALSG-CS)-17 - JALSG-CS-17

Japan Adult Leukemia Study Group (JALSG)0 个研究点目标入组 6,542 人开始时间: 2017年6月29日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)With a history of chemotherapy or hematopoietic stem cell transplantation in AML, MDS or CMML; however, treatment-related AML, MDS and CMML which developed after the following therapies are included: therapy for preceding blood abnormalities (such as immunosuppressive therapy for aplastic anemia), chemotherapy for malignancy of other tissues, radiation therapy (such as radiation therapy for preceding breast cancer, chemotherapy for preceding malignant lymphoma). (2)In case of progress from MDS or CMML to AML, re-registration is not required if it is registered with preceding MDS or CMML. MDS and CMML which had already been diagnosed outside the JALSG participating institutions are excluded. The case which developed to AML after having been diagnosed as MDS by other than those institutions and transferred to the own institution is registered as AML (with preceding blood disease). (Even if the history of abnormality of blood count is long, newly diagnosed MDS and CMML in the own institution are not excluded.)

发起方

Japan Adult Leukemia Study Group (JALSG)